34385-94-9

Usage

Uses

Used in Organic Synthesis:
5-CHLORO-2,3-DIHYDRO-1-BENZOFURAN-2-CARBOXYLIC ACID is used as a building block in organic synthesis for the preparation of various pharmaceuticals and bioactive molecules. Its unique structure and functional groups contribute to the development of new compounds with potential applications in medicine.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-CHLORO-2,3-DIHYDRO-1-BENZOFURAN-2-CARBOXYLIC ACID is utilized for its potential pharmacological activity. The benzofuran core in 5-CHLORO-2,3-DIHYDRO-1-BENZOFURAN-2-CARBOXYLIC ACID may confer properties that make it a valuable candidate in drug discovery and development, particularly for the creation of novel therapeutic agents.
Used in Drug Discovery and Development:
5-CHLORO-2,3-DIHYDRO-1-BENZOFURAN-2-CARBOXYLIC ACID is employed in drug discovery and development due to its potential to be a key component in the synthesis of new drugs. Its structural features and the presence of the benzofuran core make it a promising candidate for the design and synthesis of pharmaceuticals with improved therapeutic effects and reduced side effects.
Used in Pharmaceutical Industry:
5-CHLORO-2,3-DIHYDRO-1-BENZOFURAN-2-CARBOXYLIC ACID is used as a key intermediate in the pharmaceutical industry for the synthesis of various drugs and drug candidates. Its versatility in chemical reactions and the ability to be modified or functionalized make it an essential component in the development of new medications.
Used in Bioactive Molecule Synthesis:
In the synthesis of bioactive molecules, 5-CHLORO-2,3-DIHYDRO-1-BENZOFURAN-2-CARBOXYLIC ACID is utilized for its potential to contribute to the development of compounds with biological activity. Its unique structure and functional groups can be exploited to create molecules with specific therapeutic targets, enhancing the effectiveness of treatments in various medical conditions.

InChI:InChI=1/C9H7ClO3/c10-6-1-2-7-5(3-6)4-8(13-7)9(11)12/h1-3,8H,4H2,(H,11,12)

Upstream product

• 10242-10-1 5-chlorobenzofuran-2-carboxylic acid 
• 1914-60-9 2,3-dihydro-1-benzofuran-2-carboxylic acid 
• 312608-45-0 (+/-)-2-hydroxymethyl-5-chloro-2,3-dihydro-1-benzofuran 
• 13997-73-4 2-allyl-4-chlorophenol 
• 13997-70-1 1-allyloxy-4-chlorobenzene 
• 106-48-9 4-chloro-phenol 
• 635-93-8 5-chlorosalicyclaldehyde 
• 59962-89-9 ethyl 5-chlorobenzofuran-2-carboxylate 

Downstream Products

• 312608-45-0 (+/-)-2-hydroxymethyl-5-chloro-2,3-dihydro-1-benzofuran 
• 55169-15-8 (+/-)-5-chloro-2,3-dihydro-1-benzofuran-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

COMPOUNDS, COMPOSITIONS AND METHODS

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF

The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X1, X2, X3, X4, X5, X6, X7 and X8 are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.

Further structure-activity relationships in the series of tropanyl esters endowed with potent antinociceptive activity

Several analogs of the α-tropanyl esters of 2-(4-chlorophenoxy)butyric acid (SM21) and 2-phenylthiobutyric acid (SM32), endowed with potent antinociceptive and cognition enhancing activity, were synthesized, aimed at obtaining more potent and safe drug candidates. Variation of the acyl moiety, as well as the conformational restriction of atropine to give the α-tropanyl ester of 2,3-dihydrobenzofurane-3-carboxylic acid (18), practically abolished activity. In the case of 18, the antimuscarinic activity was also severely affected by the conformation restrain. On the contrary, conformational restriction of phenoxybutyric and phenylthiobutyric acid derivatives to give the α-tropanyl ester of 2,3-dihydro-benzofurane-2-carboxylic acid and 2,3-dihydro-benzothiophene-2-carboxylic acid, afforded potent analgesic drugs that unfortunately were too toxic to be reliable drug candidates. A series of related esters of benzofurane-3-carboxylic acid and benzothiophene-3-carboxylic acid were also studied and found to be potent but toxic analgesics.

α-Adrenoreceptor Reagents. 2. Effects of Modification of the 1,4-Benzodioxan Ring System on α-Adrenoreceptor Activity

Modification of the 1,4-benzodioxan ring present in RX 781094 (1) has not previously been considered.This paper describes a number of analogues of this ring system, including compounds in which one of the oxygen atoms has been replaced by a methylene group and also those in which the ring size has been changed to give, for example, furan and thiophene derivatives.The dihydroxybenzofuranylimidazoline compound 7 is the only analogue possesing presynaptic antagonist potency and selectivity comparable to that of 1.In view of this result, a number of derivatives was prepared to determine the structure-activity relationships within this series.Many derivatives, as well as the parent compound 7, were found to possess presynaptic α2-adrenoreceptor antagonist and postsynaptic α1-adrenoreceptor partial agonist properties.Two of the selective presynaptic antagonists,13 and 14, possess greater potency and selectivity than that possessed by 1.The 5-chloro derivative 25 is twice as potent as 1 after oral administration but only about half as potent when given intravenously.